Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer

BMC Cancer

Volumn 7, Issue , 2007, Pages

  Makris, Demosthenes ^a   Scherpereel, Arnaud ^a,b   Copin, Marie Christine ^a   Colin, Guillaume ^a   Brun, Luc ^a   Lafitte, Jean ^a   Marquette, Charles ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; DOCETAXEL; ERLOTINIB; GEMCITABINE; IFOSFAMIDE; METHYLPREDNISOLONE; MITOMYCIN; NAVELBINE; OXYGEN; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ACUTE RESPIRATORY FAILURE; ADULT; ARTICLE; AUTOPSY; BACTERIAL INFECTION; CANCER STAGING; CASE REPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE HEART FAILURE; COUGHING; DEATH; DRUG ERUPTION; DRUG FATALITY; DRUG WITHDRAWAL; DYSPNEA; FEVER; FOLLOW UP; FORCED EXPIRATORY VOLUME; HEMOPTYSIS; HOSPITAL ADMISSION; HUMAN; HYPOXEMIA; INTERSTITIAL LUNG DISEASE; LUNG CANCER; LUNG INFARCTION; LUNG INFILTRATE; MALE; MYCOSIS; NOCARDIOSIS; PERIPHERAL EDEMA; PNEUMOCYSTOSIS; PNEUMONIA; RADIODIAGNOSIS; RESPIRATORY DISTRESS; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; TACHYPNEA; THORAX PAIN; VEIN DILATATION; VIRUS INFECTION; CAUSE OF DEATH; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; FATALITY; LUNG TUMOR; MIDDLE AGED; RADIOGRAPHY;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CAUSE OF DEATH; FATAL OUTCOME; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34548509696     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-7-150     Document Type: Article

References (10)

1. Cohen MH Johnson JR Chen YF Sridhara R Pazdur R FDA drug approval summary: Erlotinib (Tarceva) tablets The Oncologist 2005, 10:461-466. 10.1634/theoncologist.10-7-461 16079312
2. Tammaro KA Baldwin PD Lundberg AS Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa) J Oncol Pharm Pract 2005, 11:127-130. 10.1191/1078155205jp158cr 16390601
3. Inoue A Saijo Y Maemondo M Gomi K Tokue Y Kimura Y Ebina M Kikuchi T Moriya T Nukiwa T Severe acute interstitial pneumonia and gefitinib Lancet 2003, 361:137-139. 10.1016/S0140-6736(03)12190-3 12531582
4. Pavlakis N Bell DR Millward MJ Levi JA Fatal pulmonary toxicity resulting from treatment with gemcitabine Cancer 1997 80:286-91 10.1002/ (SICI)1097-0142(19970715)80:2<286::AID-CNCR17>3.0.CO;2-Q 9217042
5. Orwoll ES Kiessling PJ Patterson JR Interstitial pneumonia from mitomycin Ann Intern Med 1978, 89:352-355. 686548
6. Kouroukis C Hings I Respiratory failure following vinorelbine tartrate infusion in a patient with non-small cell lung cancer Chest 1997, 112:846-848. 9315826
7. Read WL Mortimer JE Picus J Severe Interstitial Pneumonitis Associated with Docetaxel Administration Cancer 2002, 94:847-853. 10.1002/ cncr.10263 11857321
8. Baker WJ Fistel SJ Jones RV Weiss RB Interstitial pneumonitis associated with ifosfamide therapy Cancer 1990, 65:2217-2221. 10.1002/ 1097-0142(19900515)65:10<2217::AID-CNCR2820651009>3.0.CO;2-R 2112039
9. Shih YN Chiu CH Tsai CM Perng RP Interstitial pneumonia during gefitinib treatment of non-small-cell lung cancer J Chin Med Assoc 2005, 68:183-186. 15850069
10. Fukuoka M Yano S Giaccone G Tamura T Nakagawa K Douillard JY Nishiwaki Y Vansteenkiste J Kudh S Rischin D Eek R Horai T Noda K Taketa I Smit E Averdush S Macleod A Feyereislova A Dong RP Baselga J Multi-Institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer J Clin Oncol 2003, 21:2237-2246. 10.1200/JCO.2003.10.038 12748244